About

Andrew Miller, Ph.D., serves as Senior Vice President and Head of Translational Medicine and Early Development at ADAXION Therapeutics, where he bridges the gap between therapeutic discovery and clinical development. His extensive background in the biotechnology industry spans over 22 years in both small molecule and biologic immunotherapeutic drug development from discovery to Phase 1 studies.

Andrew started his career as an Investigator at Novartis’ La Jolla campus where, during his 13 year tenure, he led numerous therapeutic programs in autoimmunity, cancer immunotherapy, and vaccines. Before joining ADAXION, Andrew co-founded a clinical stage biotech, Apros Therapeutics, where he served as VP of Immunology and Operations, and co-founded a sister company, Nexys Therapeutics, serving as Head of Biology. Over the course of Andrew’s career in R&D, he has played an integral role on 6 clinical stage programs. Andrew holds a Ph.D. in Immunology & Virology from UMass Chan Medical School and a bachelor’s in finance and operations management from UMass Amherst.